Zydus Wellness (531335) Q4 98/99 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 98/99 earnings summary
3 Nov, 2026Executive summary
FY99 sales reached Rs 1,45,16,535 versus Rs 4,85,083 in FY98, while the year ended with a loss before tax of Rs 45,36,571.
Operations ran amid continuing competitive conditions; management expected improvement through greater market penetration.
Financial highlights
Sales were Rs 1,45,16,535; total income was Rs 1,53,57,478, including interest income of Rs 1,69,400 and a stock increase of Rs 6,71,543.
Total expenditure was Rs 1,98,94,049 and loss before tax was Rs 45,36,571; the financial abstract reports the same loss after tax.
Raw material consumed was Rs 1,01,88,206; depreciation was Rs 49,25,999 and preliminary expenses written off were Rs 5,02,698.
Outlook and guidance
Operations were expected to improve through greater market penetration.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Sales rose, but FY98 ended with a Rs. 78.8 lakh net loss.531335
Q4 97/98 - Revenue rose 42%, profit after tax doubled, and a Rs. 0.60/share dividend was proposed.531335
Q4 02/03 - Higher sales and production accompanied a narrower loss, but operating cash flow remained negative.531335
Q4 99/00 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Sales more than doubled as profits rose and product expansion broadened.531335
Q4 03/04 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Revenue surged 49%, but profit eased amid advertising investment; Nutralite Premium launched.531335
Q4 06/07 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06